The FDA approved oral brensocatib (Brinsupri) as the first treatment for non-cystic fibrosis bronchiectasis in adults and kids 12 years and up, drugmaker Insmed announced on Tuesday.

A first-in-class reversible dipeptidyl peptidase-1 (DPP-1) inhibitor, brensocatib addresses the underlying inflammatory process of the serious chronic lung disease, which can lead to permanent lung damage and affects roughly half a million people in the U.S.

People with non-cystic fibrosis bronchiectasis are vulnerable to persistent inflammation and repeated respiratory infections as the progressive disease permanently widens the airways and makes it difficult to clear mucus and bacteria. The frequent exacerbations patients experience can involve chronic coughing, excessive sputum production, dyspnea, and

See Full Page